Related Experiment Video

Updated: Aug 17, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Discovery and validation of drug targets for tumour angiogenesis

Gabriel Kremmidiotis, Tina C Lavranos

    Expert Opinion on Therapeutic Targets
    |June 7, 2005
    PubMed

    Insights

    New anti-cancer drugs targeting blood vessel formation (angiogenesis) are in development. Validating numerous gene targets requires efficient experimental platforms for effective cancer therapy.

    Area of Science:

    • Oncology and Molecular Biology
    • Biomedical Engineering

    Background:

    • Tumorigenesis relies on angiogenesis, the formation of new blood vessels, which is crucial for tumor growth and metastasis.
    • Inhibiting angiogenesis is a therapeutic strategy for cancer treatment, with many drugs in development.
    • Numerous genes regulated during in vitro angiogenesis present potential targets for novel anti-cancer drugs.

    Discussion:

    • Identifying and validating hundreds of potential angiogenesis drug targets necessitates advanced experimental technology platforms.
    • These platforms should facilitate dynamic, simultaneous target selection, filtering, and validation.
    • A funnel-like approach is needed to progressively narrow down numerous candidates to a manageable few.

    Key Insights:

    • Efficient validation platforms are critical for identifying effective drug targets in cancer angiogenesis.
    • The development of targeted therapies requires robust methods for selecting and validating numerous gene targets.
    • Optimizing drug cocktails for diverse cancer pathologies and resistance mechanisms depends on validated targets.

    Outlook:

    • Future cancer therapies will benefit from validated angiogenesis targets, enabling precise drug screening and cocktail design.
    • Technological advancements in target validation will accelerate the development of next-generation anti-cancer drugs.
    • The integration of high-throughput screening with validated targets promises more effective and personalized cancer treatments.

    More Related Videos

    Isolation and Culture Expansion of Tumor-specific Endothelial Cells10:15

    Isolation and Culture Expansion of Tumor-specific Endothelial Cells

    Published on: October 14, 2015

    Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

    Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

    Published on: June 30, 2023

    Related Concept Videos

    Mechanism of Angiogenesis01:10

    Mechanism of Angiogenesis

    Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Regulation of Angiogenesis and Blood Supply01:24

    Regulation of Angiogenesis and Blood Supply

    Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
    Drug Discovery: Overview01:26

    Drug Discovery: Overview

    Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...